Innate Pharma Announces FDA Clearance to Proceed With TELLOMAK 3, a Confirmatory Phase 3 Trial of Lacutamab in CTCL
The planned confirmatory Phase 3 trial, TELLOMAK 3, aims to demonstrate efficacy of lacutamab in patients with Sézary syndrome (SS) and Mycosis fungoides (MF),... Read more.
mimik Ignites Abu Dhabi Edge AI Revolution—New Joint Venture Builds a Global Blueprint for Industrial Edge Agentic AI
ABU DHABI, United Arab Emirates–(BUSINESS WIRE)–#ADAutonomousSummit–mimik, a global pioneer in device-first Continuum AI and agentic software,... Read more.
Tokyo Metropolitan Government Selects Multi-Use Case Implementation Project Featuring SkyDrive and Joby Aviation Aircraft for “eVTOL Implementation Project (Phase I)”
Outline of this press release: The project proposal by the nine companies, with Nomura Real Estate as the Lead Company, was selected by the Tokyo Metropolitan Government... Read more.
e.l.f. Lands at ULTA Beauty Mexico, Expanding Accessibility to the Best of Beauty for Every Eye, Lip, and Face
e.l.f.’s presence is growing following successful market launch in 2024 OAKLAND, Calif.–(BUSINESS WIRE)–e.l.f. Beauty (NYSE: ELF), the bold disruptor... Read more.
Kaneka Expands Global Reach with i-ED COIL™ Launch in Europe
TOKYO–(BUSINESS WIRE)–Kaneka Corporation (Headquarters: Minato-ku, Tokyo; President: Kazuhiko Fujii) (TOKYO:4118) has begun sales of its i-ED COIL™,... Read more.
Vir Biotechnology Announces AASLD The Liver Meeting® Presentation & New England Journal of Medicine Publication of Phase 2 Data Demonstrating Tobevibart & Elebsiran Combination Deliver High Rates of Undetectable HDV RNA with Favorable Safety Profile
SOLSTICE trial data demonstrate that 66% of chronic hepatitis delta participants receiving a monthly dose of tobevibart and elebsiran achieved undetectable HDV RNA... Read more.
V.F. Corporation 72 Hour Deadline Alert: Former Louisiana Attorney General And Kahn Swick & Foti, LLC Remind Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuits Against V.F. Corporation – VFC
NEW YORK & NEW ORLEANS–(BUSINESS WIRE)–Kahn Swick & Foti, LLC (“KSF”) and KSF partner, the former Attorney General of Louisiana, Charles... Read more.
Virion Therapeutics Reports Progress Towards HBV Functional Cure with Sustained and Continued HBsAg Declines up to One Year After a Single VRON-0200 Dose From its Phase 1b Study at AASLD’s The Liver Meeting® 2025
Highlights from the Data Presentation VRON-0200 was safe and well tolerated, with no serious treatment-related adverse events, treatment discontinuations, or treatment-related... Read more.
Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Adults with Heterozygous Familial Hypercholesterolemia (HeFH) in Phase 3 CORALreef HeFH Trial
Enlicitide has the potential to be the first approved oral PCSK9 inhibitor designed to deliver antibody-like efficacy and help address critical unmet needs for patients... Read more.
Baxdrostat demonstrated a statistically significant and highly clinically meaningful placebo-adjusted reduction of 14.0 mmHg in 24-hour ambulatory systolic blood pressure in patients with resistant hypertension in the Bax24 Phase III trial
Baxdrostat demonstrated a statistically significant placebo-adjusted reduction of 13.9 mmHg in night-time ambulatory systolic blood pressure at 12 weeks with a safety... Read more.